Next Article in Journal
Prevention of Progression in Myopia: A Systematic Review
Previous Article in Journal
Association between eNOS Gene Polymorphism (T786C and VNTR) and Sickle Cell Disease Patients in Ghana

When to Initiate Weight Loss Medications in the NAFLD Population

Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA
Drexel University College of Medicine, Philadelphia, PA 19129, USA
Department of Medicine, Mary Imogene Bassett Hospital, Cooperstown, NY 13326, USA
Author to whom correspondence should be addressed.
Diseases 2018, 6(4), 91;
Received: 9 August 2018 / Revised: 18 September 2018 / Accepted: 26 September 2018 / Published: 30 September 2018
Nonalcoholic fatty liver disease (NAFLD) is characterized by histological evidence of hepatic steatosis, lobular inflammation, ballooning degeneration and hepatic fibrosis in the absence of significant alcohol use and other known causes of chronic liver diseases. NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL is generally benign but can progress to NASH, which carries a higher risk of adverse outcomes including cirrhosis, end-stage liver disease, hepatocellular carcinoma and death if liver transplantation is not pursued in a timely fashion. Currently, lifestyle modifications including healthy diet and increased physical activity/exercise culminating in weight loss of 5% to >10% is the cornerstone of treatment intervention for patients with NAFLD. Patients with NAFLD who fail to obtain this goal despite the help of dietitians and regimented exercise programs are left in a purgatory state and remain at risk of developing NASH-related advance fibrosis. For such patients with NAFLD who are overweight and obese, healthcare providers should consider a trial of FDA-approved anti-obesity medications as adjunct therapy to provide further preventative and therapeutic options as an effort to reduce the risk of NAFLD-related disease progression. View Full-Text
Keywords: NAFLD; NAFL; NASH; weight loss medication; weight loss; nutrition NAFLD; NAFL; NASH; weight loss medication; weight loss; nutrition
MDPI and ACS Style

Yoo, E.R.; Sallam, S.; Perumpail, B.J.; Iqbal, U.; Shah, N.D.; Kwong, W.; Cholankeril, G.; Kim, D.; Ahmed, A. When to Initiate Weight Loss Medications in the NAFLD Population. Diseases 2018, 6, 91.

AMA Style

Yoo ER, Sallam S, Perumpail BJ, Iqbal U, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. When to Initiate Weight Loss Medications in the NAFLD Population. Diseases. 2018; 6(4):91.

Chicago/Turabian Style

Yoo, Eric R., Sandy Sallam, Brandon J. Perumpail, Umair Iqbal, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, and Aijaz Ahmed. 2018. "When to Initiate Weight Loss Medications in the NAFLD Population" Diseases 6, no. 4: 91.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop